## Table 3

## In this guide

## In this guide

- 1. Table 3 Annex A
- 2. Table 4 Annex A
- 3. Table 5 Annex A
- 4. Table 6 Annex A
- 5. Table 7 Annex A
- 6. Table 8 Annex A
- 7. Table 9 Annex A
- 8. Table 10 Annex A
- 9. Table 11 Annex A
- 10. Table 12 Annex A
- 11. Table 13 Annex A
- 12. Table 14 Annex A
- 13. Table 15 Annex A
- 14. Table 16 Annex A
- 15. Table 17 Annex A
- 16. Table 18 Annex A
- 17. Table 19 Annex A
- 18. Table 20 Annex A
- 19. Table 21 Annex A

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

## **Table 3. Acute toxicity studies for PFCAs - PFOA**

\*Derived by contractor; \*\* calculated according to EFSA. (2012); NR - not reported; NA - not applicable.

|        |                                 | species<br>/ sex /       | (GL) study                            | (μg/mL / μg/g<br>)                           | Observed effects at LOAEL ( controls vs treated groups).  Recovery ( controls vs treated groups). | Published<br>NOAEL /<br>LOAEL<br>(mg/kg<br>bw) | Study authorions   |
|--------|---------------------------------|--------------------------|---------------------------------------|--|---|--|--|
|        |                                 |                          |                                       |  | Males:  |  |  |
|        |                                 |                          | 0 or 40                               |  | ↑ mRNA of cyp2B10,  |  |  |
|        | PFOA                            | C57BL/6,<br>mice<br>Male | Propylene                             | col:water  Ingle dose NR  In-GL  Indy  P not | 3A11 and<br>4A14 in liver<br>(data only<br>reported in<br>figures).<br>↑ protein                  | Males:<br>NA / 40*                             | PFOA increased the expression of Cyp2B10 and 4A14 in mous liver. |
|        | CAS No. not given 96%.          |                          | i.p.                                  |  |   |  |  |
|        |                                 |                          | Single dose                           |  |   |  |  |
| Klaass | Cheng and<br>Klaassen<br>(2008) | 5/dose.                  | Non-GL<br>study<br>GLP not<br>stated. |  | levels of cyp2B and 4A in liver (data only reported in figures).                                  |  |  |
|        |                                 |                          |                                       |  | Recovery not assessed.  |  |  |

Dose (mg/kg

| Substance / CAS no. / purity / reference   | train&<br>pecies<br>sex /<br>o. of<br>nimals | duration /  | (μg/mL / μg/g<br>) | arounc)  | Published<br>NOAEL /<br>LOAEL<br>(mg/kg<br>bw) | Study authorsions  |
|--|--|---|--------------------|--|--|--|
| (ammonium mi<br>salt) (w<br>CAS No. not <sup>tyl</sup><br>given PP<br>nu<br>97%.<br>Ma | V129 nice vild vpe and PAR-α ull) lale       | 0 or 10 m/kg bw/day. Deionized water, Gavage, 7 days, Non-GL study, GLP not stated. | NR                 | Males:  ↑ absolute and relative liver weight (data only reported in figures).  ↑ lipid and TGs (data only reported in figures).  Changes in mRNA related to transport, fatty acid, TG and cholesterol synthesis and omega oxidation. | Males:<br>NA / 10                              | PFOA caused extensive micro and macro-vesicular steatosis in hepatocytes and that the steatosis was associated with increase in the accumulation of TG in the liver. |
|  |  |   |                    | Recovery not assessed.   |  |  |

Dose

| Substance s / CAS no. / purity / reference | Strain&<br>species<br>sex /<br>no. of<br>animals | _ | Observed effects at LOAEL ( controls vs treated groups).  Recovery ( controls vs treated groups). | Published<br>NOAEL /<br>LOAEL<br>(mg/kg<br>bw) | Study authorions |
|--|--|---|---|--|------------------|
|  |  |   |   |  | <b>T</b> I I' I' |

The objective of the work was to characterize PFOA-induce hepatomegal in male rats, particularly with respect the potential role of PPAR--mediated ce proliferation and possible decreased apoptosis.

Clinical
chemistry
findings were
consistent
with those
associated
with PPAR
activation,
notably
decreased
serum total

Males (mean ± SD):

↑ hepatic cell proliferation (%): 0.22 ± 0.14 vs 0.74 ± 0.55,

0 or 300

| Substance<br>/ CAS no. /<br>purity /<br>reference                | Strain&<br>species<br>/ sex /<br>no. of<br>animals | •  | PFAS<br>concentration<br>(μg/mL / μg/g<br>) | Observed effects at LOAEL ( controls vs treated groups).  Recovery ( controls vs treated groups).  | Published<br>NOAEL /<br>LOAEL<br>(mg/kg<br>bw) | Study authorions  |
|--|--|--|---|--|--|---|
| PFOA CAS No. not given Purity not given. Kawashima et al. (1995) | Wistar<br>rats<br>Male<br>4/dose.                  | 0, 0.0025,<br>0.005, 0.01,<br>0.02 or<br>0.04%<br>equivalent<br>to 0, 3, 6,<br>12, 24 or<br>48**,<br>i.p.<br>5 days,<br>Non-GL<br>study.<br>GLP not<br>stated. | NR  | Males:  ↑ acyl transferase activity (data only reported in figures).  ↓ GSH S- transferase (data only reported in figures).  ↑ TG (data only reported in figures).  Recovery not assessed. | Males:<br>NA / 3*                              | Morphological studies demonstrated that the administration of PFOA resulted in a marked proliferation peroxisomes in hepatocytes.  PFOA produced triacylglycerol and cholesterol accumulation in liver. This seems inconsistent with the marked inductions of both peroxisome proliferation |

Dose